Products & Services

iCell® Hematopoietic Progenitor Cells

A Reliable Source of Human Blood Cell Precursors

Mature human blood cells have a finite lifespan and must be regenerated continually from hematopoietic progenitor cells (HPCs) that reside in the bone marrow. These HPCs self-renew to ensure a constant, lifelong supply of blood cells. HPCs represent a relatively rare population of cells. They have the capacity to proliferate and differentiate into red blood cells, white blood cells, and platelets. Human HPCs used in therapeutic development programs that target various clinical conditions are currently obtained from various human donor sources, which by their nature can be difficult to obtain and exhibit high donor-to-donor variability.

CDI scientists have used iPS cell technology to develop iCell® Hematopoietic Progenitor Cells. These human CD34+ cells are multipotent, as demonstrated in CFU assays, and can be further differentiated into a variety of blood cell types that have utility for:

  • Cancer immunotherapy development
  • Induced transplant tolerance studies
  • Autoimmune disease research
  • Hematotoxicity testing
  • Hematopoiesis mechanisms research